Hospital groups challenged Eli Lilly’s decision to withhold 340B discounts from hospitals that refuse to submit claims data, calling the policy unlawful. The dispute centers on whether Lilly can impose compliance requirements that affect participation in a federal drug pricing program. The company’s stated approach follows a “threat to withhold” line of action tied to a data submission condition, prompting legal and operational friction with covered entities that rely on 340B pricing for patient access. Hospital groups argue the manufacturer has no legal authority to set its own compliance terms for the federal program. For biotech and payers, the episode is a reminder that 340B implementation risk is shifting from policy interpretation to real-world provider engagement and manufacturer data demands. Any escalation could affect discount participation rates, pricing expectations, and near-term contract negotiations.